Clinical Trial Update: Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update examining determinants of resistance to endocrine therapy and the effect of a CDK4/6 inhibitor in hormone receptor-positive metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Metastatic Breast Cancer

Drugs mentioned

• CDK4/6 inhibitor (unspecified)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Breast Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING